Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Cancer drugs in the United States: Justum Pretium--the just price.

Kantarjian HM, Fojo T, Mathisen M, Zwelling LA.

J Clin Oncol. 2013 Oct 1;31(28):3600-4. doi: 10.1200/JCO.2013.49.1845. No abstract available. Erratum in: J Clin Oncol. 2015 Oct 20;33(30):3523.

2.

Cancer drug prices and the free-market forces.

Kantarjian H, Zwelling L.

Cancer. 2013 Nov 15;119(22):3903-5. doi: 10.1002/cncr.28330. No abstract available.

3.

The just price of cancer drugs and the growing cost of cancer care: oncologists need to be part of the solution.

Pfister DG.

J Clin Oncol. 2013 Oct 1;31(28):3487-9. doi: 10.1200/JCO.2013.50.3466. No abstract available.

PMID:
24002517
4.

Expensive cancer therapies: unintended effects.

Delude CM.

J Natl Cancer Inst. 2015 Jan 6;107(1):497. doi: 10.1093/jnci/dju497. No abstract available.

PMID:
25564602
5.

Market spiral pricing of cancer drugs.

Light DW, Kantarjian H.

Cancer. 2013 Nov 15;119(22):3900-2. doi: 10.1002/cncr.28321. No abstract available.

6.

Can treatment costs be tamed?

Malakoff D.

Science. 2011 Mar 25;331(6024):1545-7. doi: 10.1126/science.331.6024.1545. No abstract available.

PMID:
21436438
7.

Soaring price of cancer drugs leads plans to new approaches.

Sipkoff M.

Manag Care. 2007 Aug;16(8):12-3. No abstract available.

8.

US hospitals object to changes in Genentech drug distribution.

Furlow B.

Lancet Oncol. 2014 Dec;15(13):e591. doi: 10.1016/S1470-2045(14)71040-X. No abstract available. Erratum in: Lancet Oncol. 2014 Dec;15(13):e587.

PMID:
25499290
9.

Cost effectiveness and cancer drugs.

Battley JE, Connell LC, Graham DM, O'Reilly S.

J Clin Oncol. 2014 Apr 1;32(10):1091-2. doi: 10.1200/JCO.2013.53.9932. No abstract available.

PMID:
24590642
10.

Why clinical oncologists should talk about the price of cancer drugs.

Berlinger N.

Virtual Mentor. 2013 Aug 1;15(8):677-80. doi: 10.1001/virtualmentor.2013.15.8.jdsc1-1308. No abstract available.

11.

Oral/infusion cancer drug parity begins to raise health plan costs.

Carroll J.

Manag Care. 2012 Jan;21(1):7-8. No abstract available.

12.

The high cost of cancer drugs and what we can do about it.

Siddiqui M, Rajkumar SV.

Mayo Clin Proc. 2012 Oct;87(10):935-43. doi: 10.1016/j.mayocp.2012.07.007. No abstract available.

13.

Health policy: Putting a price on cancer.

Sullivan R, Aggarwal A.

Nat Rev Clin Oncol. 2016 Mar;13(3):137-8. doi: 10.1038/nrclinonc.2016.12. No abstract available.

PMID:
26856742
14.

Role of the 340B Drug Discount Program in Recent Cancer Care Trends.

Kantarjian HM, Chapman R.

J Oncol Pract. 2015 Jul;11(4):303-7. doi: 10.1200/JOP.2014.002139.

PMID:
26036268
15.

Seeking value as cancer drug costs soar.

Bender E.

Cancer Discov. 2013 Aug;3(8):833-4. doi: 10.1158/2159-8290.CD-ND2013-018.

16.

Paying a high price for cancer drugs.

[No authors listed]

Lancet. 2015 Aug 1;386(9992):404. doi: 10.1016/S0140-6736(15)61431-3. No abstract available.

PMID:
26251376
17.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC Jr, Bennett JM, Benz EJ Jr, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ Jr, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA.

Mayo Clin Proc. 2015 Aug;90(8):996-1000. doi: 10.1016/j.mayocp.2015.06.001. No abstract available.

18.

Chemotherapy treatment options and policies.

Breshears Wheeler J, Hanson K.

NCSL Legisbrief. 2012 May;20(19):1-2. No abstract available.

PMID:
22666895
19.

News feature: Costly US anticancer drugs pose problems for doctors and patients.

Charatan F.

BMJ. 2008 Jul 14;337:a778. doi: 10.1136/bmj.a778. No abstract available.

20.

Reply to J.E. Battley et al.

Pfister DG, Baxi SS.

J Clin Oncol. 2014 Apr 1;32(10):1092-3. doi: 10.1200/JCO.2013.54.3017. No abstract available.

PMID:
24590648

Supplemental Content

Support Center